Skip to main content

Table 2 Pathologic response per protocol arm

From: TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer

GroupLetrozole, n = 24Letrozole/bevacizumab, n = 45
n (%)95% CIn (%)95% CI
Pathologic CR (pCR)none (0)0, 14.2%5^ (11)3.7%, 24.1%
pCR and microscopic residual diseasenone (0)0, 14.2%9 (20)9.6%, 34.7%
pCR and microscopic residual disease—(ITT)*none (0)0, 14.2%9 (18)8.6%, 31.4%
Partial response9 (37.5)18.8%, 59.4%20 (44.4)29.6%, 60.0%
Objective response rate9 (37.5)18.8%, 59.4%29 (64.4)48.8%, 78.1%
Stable disease12 (50)29.1%, 70.9%13 (28.8)16.4%, 44.3%
Progressive disease3 (12.5)2.7, 32.4%3 (6.6)1.4%, 18.3%
Downstage (3/2 to 0/1)9 (37.5)18.8%, 59.4%20 (44.4)29.6%, 60.0%
Node reversion
(positive to negative)
4/15 (26.6)7.8%, 55.1%10/25 (40)21.1%, 61.3%
  1. Exact (Clopper-Pearson) confidence interval
  2. ^One of the 5 patients who achieved a pCR had residual ductal carcinoma in situ
  3. *ITT (intention to treat population): this analysis assumes that none of the patients who did not undergo surgery (letrozole group, n = 1; letrozole/bevacizumab group, n = 5) achieved a pCR or microscopic residual disease